Huaqiang Zhou,Jiaqing Liu,Jiayi Shen et al.
Huaqiang Zhou et al.
Incidentally Detected Small Cell Transformation in a Patient With Resected Oligometastatic EGFR-Mutated Lung Cancer Treated With Osimertinib [0.03%]
接受奥希替尼治疗的寡转移EGFR突变肺癌患者中偶然发现的小细胞转化
Carlos Henrique A Teixeira,Evandro S de Mello,Cheng Tzu Yen et al.
Carlos Henrique A Teixeira et al.
Tracheobronchial and Pulmonary Amyloidosis Mimicking Pulmonary Metastases in a Patient With Lung Adenocarcinoma [0.03%]
肺腺癌患者气管支气管及肺淀粉样变模仿肺转移病变一例
Mao Uematsu,Tomonari Kinoshita,Naomichi Sasaki et al.
Mao Uematsu et al.
Appendiceal Metastasis From Thymic Carcinoma: An Unusual Presentation of a Rare Cancer [0.03%]
胸腺癌的阑尾转移：一种罕见癌症的不常见表现形式
Shannon Swift,Osório Lopes Abath Neto,Mohammad Hadi Bagheri et al.
Shannon Swift et al.
Numbers and Stations: Impact of Examined Lymph Node on Precise Staging and Survival of Radiologically Pure-Solid NSCLC: A Multi-Institutional Study [0.03%]
数量与分期：检查淋巴结对影像学纯实性NSCLC精准分期和生存的影响：多中心研究
Donglai Chen,Yiming Mao,Junmiao Wen et al.
Donglai Chen et al.
Objectives: To determine the optimal number of examined lymph nodes (ELNs) and examined node stations (ENSs) in patients with radiologically pure-solid NSCLC and to investigate the impact of ELNs and ENSs on accurate stag...
Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement [0.03%]
ALK阳性的非小细胞肺癌食管转移导致的食管狭窄在使用Lorlatinib治疗几天后未放置支架的情况下得到解决
Vito Longo,Annamaria Catino,Michele Montrone et al.
Vito Longo et al.
Sai-Hong Ignatius Ou,Viola W Zhu
Sai-Hong Ignatius Ou
Since the discovery of RET fusion-positive (RET+) NSCLC around late 2011 to early 2012, clinical trials of multikinase inhibitors and highly potent and selective RET tyrosine kinase inhibitors have indicated that RET fusion is an actionable...
TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma [0.03%]
TPD52L1-ROS1重排作为肺癌腺癌奥希替尼获得性耐药新机制对克唑替尼联合奥希替尼治疗有反应
Caihua Xu,Dapeng Li,Weiming Duan et al.
Caihua Xu et al.
Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease [0.03%]
基于血液的监视对患有小细胞肺癌患者的循环肿瘤DNA的检测可发现疾病复发并预测限局期疾病的患者死亡
Wade T Iams,Prasad R Kopparapu,Yingjun Yan et al.
Wade T Iams et al.
Introduction: Most patients (70%) with limited-stage SCLC (LS-SCLC) who are treated with curative-intent therapy suffer disease relapse and cancer-related death. We evaluated circulating tumor DNA (ctDNA) as a predictor o...
Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report [0.03%]
在非小细胞肺癌患者中，EGFR酪氨酸激酶抑制剂耐药时可能频繁存在致癌融合：简报
Diego Enrico,Ludovic Lacroix,Jeanne Chen et al.
Diego Enrico et al.
Introduction: Despite initial benefit, virtually all patients suffering from EGFR-mutant NSCLC experience acquired resistance to tyrosine kinase inhibitors (TKIs), driven by multiple mechanisms. Recent reports have identi...